Research and Markets: Levosimendan – Patent, Extension and Data Exclusivity Expiry Snapshot – Covers Over 50 Countries and 1600 Molecules, Including Over 300 Biologics

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/9tp7fm/levosimendan) has announced the addition of the “Levosimendan – Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)” report to their offering.

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know.

Watertight, user-friendly data you can rely on

• Key patent, extension and data exclusivity expiry in one simple view
• Highly accurate, manually verified data
• Full consideration of paediatric, orphan and complex data exclusivity
• Covers over 50 countries and 1600 molecules, including over 300 biologics

Insight and understanding for all levels of expertise

• Patents interpreted and assigned to categories
• Expert constraint analysis, commentary, and SPC validity flags
• Flags indicate constraining, difficult or nuisance patents
• Available on a per-molecule basis

Key Topics Covered:

Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 9 countries (50 country coverage also available), regulatory issues and key players.

Examples of information found in this online report include:

• Includes key patent publications for 9 main countries
• Extension and data exclusivity expiry in one simple view
• Expert constraint analysis, commentary, and SPC validity flags
• SPC analyser
• Full consideration of paediatric,orphan and complex data exclusivity
• Patents interpreted and assigned to categories
• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
• DMF & Paragraph IV filings
• Litigation alerts
• Marketing authorisation holders in selected territories
• Hyper-linking to crucial patent documents and national registries enabling data verification

For more information visit http://www.researchandmarkets.com/research/9tp7fm/levosimendan.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150807005798/en/

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals